BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 17220325)

  • 21. Risk of cervical intraepithelial neoplasia grade 2 or 3 after loop electrosurgical excision procedure associated with human papillomavirus type 16 variants.
    Xi LF; Kiviat NB; Wheeler CM; Kreimer A; Ho J; Koutsky LA
    J Infect Dis; 2007 May; 195(9):1340-4. PubMed ID: 17397005
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human papillomavirus type 18 DNA load and 2-year cumulative diagnoses of cervical intraepithelial neoplasia grades 2-3.
    Xi LF; Koutsky LA; Castle PE; Wheeler CM; Galloway DA; Mao C; Ho J; Kiviat NB
    J Natl Cancer Inst; 2009 Feb; 101(3):153-61. PubMed ID: 19176451
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice.
    Khan MJ; Castle PE; Lorincz AT; Wacholder S; Sherman M; Scott DR; Rush BB; Glass AG; Schiffman M
    J Natl Cancer Inst; 2005 Jul; 97(14):1072-9. PubMed ID: 16030305
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationship between cigarette smoking and human papilloma virus types 16 and 18 DNA load.
    Xi LF; Koutsky LA; Castle PE; Edelstein ZR; Meyers C; Ho J; Schiffman M
    Cancer Epidemiol Biomarkers Prev; 2009 Dec; 18(12):3490-6. PubMed ID: 19959700
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cervical adenocarcinoma in situ: Human papillomavirus types and incidence trends in five states, 2008-2015.
    Cleveland AA; Gargano JW; Park IU; Griffin MR; Niccolai LM; Powell M; Bennett NM; Saadeh K; Pemmaraju M; Higgins K; Ehlers S; Scahill M; Johnson Jones ML; Querec T; Markowitz LE; Unger ER;
    Int J Cancer; 2020 Feb; 146(3):810-818. PubMed ID: 30980692
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
    Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
    Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Three-year longitudinal data on the clinical performance of the Abbott RealTime High Risk HPV test in a cervical cancer screening setting.
    Poljak M; Oštrbenk A; Seme K; Šterbenc A; Jančar N; Vrtačnik Bokal E
    J Clin Virol; 2016 Mar; 76 Suppl 1():S29-S39. PubMed ID: 26643051
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Type-specific oncogenic human papillomavirus infection in high grade cervical disease in New Zealand.
    Simonella LM; Lewis H; Smith M; Neal H; Bromhead C; Canfell K
    BMC Infect Dis; 2013 Mar; 13():114. PubMed ID: 23452957
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recurrent high-grade cervical lesion after primary conization is associated with persistent human papillomavirus infection in Norway.
    Vintermyr OK; Iversen O; Thoresen S; Quint W; Molijn A; de Souza S; Rosillon D; Holl K
    Gynecol Oncol; 2014 May; 133(2):159-66. PubMed ID: 24631451
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [To analyse the histopathological results of patients with HPV16/18 positive and colposcopic suspicious lesions].
    Zhang JX; Zheng TP; Liu J; Wang QX; Zhan YX; Zhang ZY
    Zhonghua Fu Chan Ke Za Zhi; 2017 Jul; 52(7):467-472. PubMed ID: 28797154
    [No Abstract]   [Full Text] [Related]  

  • 31. Changes in DNA Level of Oncogenic Human Papillomaviruses Other Than Types 16 and 18 in Relation to Risk of Cervical Intraepithelial Neoplasia Grades 2 and 3.
    Xi LF; Schiffman M; Hughes JP; Galloway DA; Koutsky LA; Kiviat NB
    Cancer Epidemiol Biomarkers Prev; 2019 Aug; 28(8):1388-1394. PubMed ID: 31101617
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multiple human papillomavirus infection with or without type 16 and risk of cervical intraepithelial neoplasia among women with cervical cytological abnormalities.
    Spinillo A; Gardella B; Roccio M; Alberizzi P; Cesari S; Patrizia M; Silini E
    Cancer Causes Control; 2014 Dec; 25(12):1669-76. PubMed ID: 25296710
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands.
    Dijkstra MG; van Zummeren M; Rozendaal L; van Kemenade FJ; Helmerhorst TJ; Snijders PJ; Meijer CJ; Berkhof J
    BMJ; 2016 Oct; 355():i4924. PubMed ID: 27702796
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of the AS04-Adjuvanted HPV16/18 Vaccine: Pooled Analysis of the Costa Rica Vaccine and PATRICIA Randomized Controlled Trials.
    Tota JE; Struyf F; Sampson JN; Gonzalez P; Ryser M; Herrero R; Schussler J; Karkada N; Rodriguez AC; Folschweiller N; Porras C; Schiffman M; Schiller JT; Quint W; Kreimer AR; Wheeler CM; Hildesheim A;
    J Natl Cancer Inst; 2020 Aug; 112(8):818-828. PubMed ID: 31697384
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe.
    Tjalma WA; Fiander A; Reich O; Powell N; Nowakowski AM; Kirschner B; Koiss R; O'Leary J; Joura EA; Rosenlund M; Colau B; Schledermann D; Kukk K; Damaskou V; Repanti M; Vladareanu R; Kolomiets L; Savicheva A; Shipitsyna E; Ordi J; Molijn A; Quint W; Raillard A; Rosillon D; De Souza SC; Jenkins D; Holl K;
    Int J Cancer; 2013 Feb; 132(4):854-67. PubMed ID: 22752992
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of HPV16 E6 variants with diagnostic severity in cervical cytology samples of 354 women in a US population.
    Zuna RE; Moore WE; Shanesmith RP; Dunn ST; Wang SS; Schiffman M; Blakey GL; Teel T
    Int J Cancer; 2009 Dec; 125(11):2609-13. PubMed ID: 19569178
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Type-dependent association between risk of cervical intraepithelial neoplasia and viral load of oncogenic human papillomavirus types other than types 16 and 18.
    Fu Xi L; Schiffman M; Ke Y; Hughes JP; Galloway DA; He Z; Hulbert A; Winer RL; Koutsky LA; Kiviat NB
    Int J Cancer; 2017 Apr; 140(8):1747-1756. PubMed ID: 28052328
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term risk of cervical intraepithelial neoplasia grade 3 or worse according to high-risk human papillomavirus genotype and semi-quantitative viral load among 33,288 women with normal cervical cytology.
    Thomsen LT; Frederiksen K; Munk C; Junge J; Iftner T; Kjaer SK
    Int J Cancer; 2015 Jul; 137(1):193-203. PubMed ID: 25471319
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of
    Lehtinen M; Lagheden C; Luostarinen T; Eriksson T; Apter D; Harjula K; Kuortti M; Natunen K; Palmroth J; Petäjä T; Pukkala E; Siitari-Mattila M; Struyf F; Nieminen P; Paavonen J; Dubin G; Dillner J
    BMJ Open; 2017 Aug; 7(8):e015867. PubMed ID: 28821519
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of cervical precancer with human papillomavirus types other than 16 among HIV co-infected women.
    Massad LS; Xie X; Burk RD; D'Souza G; Darragh TM; Minkoff H; Colie C; Burian P; Palefsky J; Atrio J; Strickler HD
    Am J Obstet Gynecol; 2016 Mar; 214(3):354.e1-6. PubMed ID: 26433170
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.